S-adenosylhomocysteine [Ligand Id: 5265] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL418052 (S-Adenosylhomocysteine, S-Adenosyl Homocysteine, S-Adenosyl-Homocysteine) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| DNA methyltransferase 1/DNA (cytosine-5)-methyltransferase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1993] [GtoPdb: 2605] [UniProtKB: P26358] | ||||||||
| ChEMBL | Inhibition of human recombinant DNMT1 expressed in Sf9 cells assessed as incorporation of [3H]S-adenosyl methionine into hemimethylated oligonucleotide substrate after 3 hrs by scintillation counting | B | 5.4 | pIC50 | 4000 | nM | IC50 | J Med Chem (2011) 54: 7663-7677 [PMID:21958292] |
| ChEMBL | Inhibition of human recombinant DNMT1 expressed in baculovirus-insect cell system by scintillation counting | B | 5.4 | pIC50 | 4000 | nM | IC50 | Bioorg Med Chem (2010) 18: 822-829 [PMID:20006515] |
| ChEMBL | Inhibition of human recombinant DNMT1 expressed in baculovirus infected high five insect cells | B | 5.7 | pIC50 | 2000 | nM | IC50 | Bioorg Med Chem Lett (2009) 19: 2747-2751 [PMID:19362833] |
| ChEMBL | Inhibition of human Dnmt1 using oligonucleotide 2 as substrate after 5000 sec by micro plate reader based real-time break-light assay | B | 6.03 | pIC50 | 941 | nM | IC50 | Bioorg Med Chem Lett (2012) 22: 3079-3082 [PMID:22483584] |
| ChEMBL | Inhibition of full length N-terminal His6-tagged human DNMT1 after 1 hr by fluorescence analysis | B | 6.05 | pIC50 | 900 | nM | IC50 | J Med Chem (2012) 55: 1731-1750 [PMID:22280363] |
| ChEMBL | Inhibition of human recombinant DNMT1 | B | 6.1 | pIC50 | 800 | nM | IC50 | Bioorg Med Chem Lett (2009) 19: 2742-2746 [PMID:19364644] |
| ChEMBL | Inhibition of DNMT1 (unknown origin) using biotinylated substrate using [3H]-SAM after 1 hr by scintillation proximity assay | B | 6.22 | pIC50 | 600 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 826-831 [PMID:30704813] |
| ChEMBL | Inhibition of DNMT1 (unknown origin) | B | 6.7 | pIC50 | 200 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| ChEMBL | Inhibition of recombinant human DNMT1 using poly(dl-dC) as substrate by hotspot assay | B | 7.15 | pIC50 | 71 | nM | IC50 | Eur J Med Chem (2020) 189: 112023-112023 [PMID:31978781] |
| DNA (cytosine-5-)-methyltransferase 3α/DNA (cytosine-5)-methyltransferase 3A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1992] [GtoPdb: 2750] [UniProtKB: Q9Y6K1] | ||||||||
| ChEMBL | Inhibition of human full length DNMT3A expressed in Sf9 cells | B | 4.3 | pIC50 | >50000 | nM | IC50 | ACS Med Chem Lett (2015) 6: 408-412 [PMID:25893041] |
| DNA (cytosine-5)-methyltransferase 3B in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6095] [UniProtKB: Q9UBC3] | ||||||||
| ChEMBL | Inhibition of human full length DNMT3B expressed in Sf9 cells | B | 4.3 | pIC50 | >50000 | nM | IC50 | ACS Med Chem Lett (2015) 6: 408-412 [PMID:25893041] |
| ChEMBL | Inhibition of human recombinant DNMT3b2 expressed in baculovirus infected high five insect cells | B | 6.52 | pIC50 | 300 | nM | IC50 | Bioorg Med Chem Lett (2009) 19: 2747-2751 [PMID:19362833] |
| ChEMBL | Inhibition of human recombinant DNMT3B expressed in baculovirus-insect cell system by scintillation counting | B | 6.6 | pIC50 | 250 | nM | IC50 | Bioorg Med Chem (2010) 18: 822-829 [PMID:20006515] |
| ChEMBL | Inhibition of human recombinant DNMT3b2 | B | 6.7 | pIC50 | 200 | nM | IC50 | Bioorg Med Chem Lett (2009) 19: 2742-2746 [PMID:19364644] |
| Histamine N-methyltransferase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2190] [UniProtKB: P50135] | ||||||||
| ChEMBL | Inhibition constant was evaluated against Histamine N-methyl-transferase | B | 4.74 | pKi | 18100 | nM | Ki | J Med Chem (1985) 28: 478-482 [PMID:3981540] |
| ChEMBL | Inhibition constant was evaluated against Histamine N-methyl-transferase | B | 4.98 | pKi | 10500 | nM | Ki | J Med Chem (1985) 28: 478-482 [PMID:3981540] |
| coactivator associated arginine methyltransferase 1/Histone-arginine methyltransferase CARM1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5406] [GtoPdb: 1255] [UniProtKB: Q86X55] | ||||||||
| ChEMBL | Inhibition of CARM1 | B | 6.07 | pKi | 860 | nM | Ki | J Med Chem (2012) 55: 8066-8074 [PMID:22924785] |
| ChEMBL | Inhibition of CARM1 (unknown origin) | B | 6.4 | pKi | 400 | nM | Ki | J Med Chem (2013) 56: 8972-8983 [PMID:23879463] |
| enhancer of zeste 1 polycomb repressive complex 2 subunit/Histone-lysine N-methyltransferase EZH1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2189116] [GtoPdb: 2835] [UniProtKB: Q92800] | ||||||||
| ChEMBL | Inhibition of EZH1 (unknown origin) by HMT assay | B | 5.19 | pIC50 | 6400 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| enhancer of zeste 2 polycomb repressive complex 2 subunit/Histone-lysine N-methyltransferase EZH2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2189110] [GtoPdb: 2654] [UniProtKB: Q15910] | ||||||||
| ChEMBL | Inhibition of EZH2 (unknown origin) | B | 4.19 | pIC50 | 65000 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| ChEMBL | Inhibition of recombinant human EZH2 using core histone as substrate by hotspot assay | B | 4.65 | pIC50 | 22600 | nM | IC50 | Eur J Med Chem (2020) 189: 112023-112023 [PMID:31978781] |
| ChEMBL | Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3. | B | 4.78 | pIC50 | 16619.3 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition of N-terminally FLAG-tagged wild type EZH2 in EZH2/SUZ12/EED/RbAp48 complex (unknown origin) expressed in baculovirus infected in SF9 cells assessed as inhibition of methylation of nucleosomes at H3K27 by scintillation counting in presence of [3H]SAM | B | 4.96 | pIC50 | 11000 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| ChEMBL | Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3. | B | 5.16 | pIC50 | 6908.2 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3. | B | 5.2 | pIC50 | 6237.9 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3. | B | 5.23 | pIC50 | 5903.4 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition Assay: Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. Compound 75 was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 5.32 | pIC50 | 4800 | nM | IC50 | US-8895245-B2. Inhibitors of human EZH2 and methods of use thereof (2014) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 5.32 | pIC50 | 4800 | nM | IC50 | US-9333217-B2. Inhibitors of human EZH2, and methods of use thereof (2016) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% TWEEN® 20 (generic: polvsorbate 20), 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated FLASHPLATE™ (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TOPCOUNT NXT HTS (Perkin Elmer). | B | 5.32 | pIC50 | 4800 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition of N-terminally FLAG-tagged EZH2 Y641N mutant in EZH2/SUZ12/EED/RbAp48 complex (unknown origin) expressed in baculovirus infected in SF9 cells assessed as inhibition of methylation of nucleosomes at H3K27 by scintillation counting in presence of [3H]SAM | B | 5.72 | pIC50 | 1900 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.33 | pIC50 | 467 | nM | IC50 | US-9333217-B2. Inhibitors of human EZH2, and methods of use thereof (2016) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% TWEEN® 20 (generic: polvsorbate 20), 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated FLASHPLATE™ (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TOPCOUNT NXT HTS (Perkin Elmer). | B | 6.33 | pIC50 | 467 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition Assay: Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. Compound 75 was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.33 | pIC50 | 467 | nM | IC50 | US-8895245-B2. Inhibitors of human EZH2 and methods of use thereof (2014) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% TWEEN® 20 (generic: polvsorbate 20), 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated FLASHPLATE™ (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TOPCOUNT NXT HTS (Perkin Elmer). | B | 6.42 | pIC50 | 380 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition Assay: Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. Compound 75 was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.42 | pIC50 | 380 | nM | IC50 | US-8895245-B2. Inhibitors of human EZH2 and methods of use thereof (2014) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.42 | pIC50 | 380 | nM | IC50 | US-9333217-B2. Inhibitors of human EZH2, and methods of use thereof (2016) |
| ChEMBL | Inhibition Assay: Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. Compound 75 was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.55 | pIC50 | 283 | nM | IC50 | US-8895245-B2. Inhibitors of human EZH2 and methods of use thereof (2014) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% TWEEN® 20 (generic: polvsorbate 20), 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated FLASHPLATE™ (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TOPCOUNT NXT HTS (Perkin Elmer). | B | 6.55 | pIC50 | 283 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.55 | pIC50 | 283 | nM | IC50 | US-9333217-B2. Inhibitors of human EZH2, and methods of use thereof (2016) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.58 | pIC50 | 263 | nM | IC50 | US-9333217-B2. Inhibitors of human EZH2, and methods of use thereof (2016) |
| ChEMBL | Inhibition Assay: Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. Compound 75 was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 μL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | B | 6.58 | pIC50 | 263 | nM | IC50 | US-8895245-B2. Inhibitors of human EZH2 and methods of use thereof (2014) |
| ChEMBL | Inhibition Assay: S-Adenosyl-L-homocysteine (SAH) was serially diluted 3 fold in DMSO for 10 points and 1 μL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 μM final concentration of SAH and negative control (0% inhibition standard) contained 1 μL of DMSO. SAH was then incubated for 30 minutes with 40 μL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% TWEEN® 20 (generic: polvsorbate 20), 0.005% BSG). A substrate mix at 10 μL per well was added which contained S-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated FLASHPLATE™ (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TOPCOUNT NXT HTS (Perkin Elmer). | B | 6.58 | pIC50 | 263 | nM | IC50 | US-9175331-B2. Inhibitors of human EZH2, and methods of use thereof (2015) |
| DOT1 like histone lysine methyltransferase/Histone-lysine N-methyltransferase, H3 lysine-79 specific in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795117] [GtoPdb: 2650] [UniProtKB: Q8TEK3] | ||||||||
| ChEMBL | Binding affinity at human recombinant DOT1L catalytic domain amino acid (1 to 472) by isothermal titration calorimetric assay | B | 6.44 | pKd | 360 | nM | Kd | J Med Chem (2012) 55: 8066-8074 [PMID:22924785] |
| ChEMBL | Binding affinity at human recombinant DOT1L catalytic domain amino acid (1 to 472)-nucleosome complex by isothermal titration calorimetric assay | B | 6.82 | pKd | 150 | nM | Kd | J Med Chem (2012) 55: 8066-8074 [PMID:22924785] |
| ChEMBL | Inhibition of DOT1-like Histone H3 Methyltransferase (unknown origin) | B | 6.57 | pKi | 270 | nM | Ki | J Med Chem (2019) 62: 10005-10025 [PMID:31188592] |
| ChEMBL | Inhibition of human recombinant DOT1L catalytic domain amino acid (1 to 472) using [3H]-SAM after 30 mins by scintillation counter | B | 6.8 | pKi | 160 | nM | Ki | J Med Chem (2012) 55: 8066-8074 [PMID:22924785] |
| ChEMBL | Competitive inhibition of recombinant human DOT1L using adenosine/deazaadenosine as substrate and SAM cofactor | B | 6.8 | pKi | 160 | nM | Ki | J Med Chem (2013) 56: 8972-8983 [PMID:23879463] |
| ChEMBL | Competitive inhibition of human recombinant DOT1L (1 to 420 amino acid residues) overexpressed in Escherichia coli BL21 (DE3) using [3H]-SAM as substrate assessed as inhibition of nucleosome methylation incubated for 30 mins prior to substrate addition measured after 1 hr by scintillation counting analysis | B | 6.22 | pIC50 | 600 | nM | IC50 | Bioorg Med Chem (2013) 21: 1787-1794 [PMID:23433670] |
| ChEMBL | Competitive inhibition of human recombinant DOT1L (1 to 472 amino acid residues) expressed in Escherichia coli BL21 (DE3) using [3H]-SAM assessed as inhibition of nucleosome methylation incubated for 10 mins prior to substrate addition measured after 30 mins by scintillation counting analysis | B | 6.22 | pIC50 | 600 | nM | IC50 | Bioorg Med Chem (2013) 21: 1787-1794 [PMID:23433670] |
| ChEMBL | Inhibition of human recombinant DOT1L (1 to 420 amino acids) expressed in Escherichia coli | B | 6.66 | pIC50 | 220 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| euchromatic histone lysine methyltransferase 2/Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6032] [GtoPdb: 2652] [UniProtKB: Q96KQ7] | ||||||||
| ChEMBL | Inhibition of G9a (unknown origin) | B | 6.24 | pKi | 570 | nM | Ki | J Med Chem (2013) 56: 8972-8983 [PMID:23879463] |
| ChEMBL | Inhibition of G9a (unknown origin) | B | 5.39 | pIC50 | 4100 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| ChEMBL | Inhibition of G9a (unknown origin) by HMT assay | B | 5.7 | pIC50 | 2000 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| ChEMBL | Inhibition of recombinant human G9a using histone H3 (1 to 21) as substrate by hotspot assay | B | 5.74 | pIC50 | 1820 | nM | IC50 | Eur J Med Chem (2020) 189: 112023-112023 [PMID:31978781] |
| euchromatic histone lysine methyltransferase 1/Histone-lysine N-methyltransferase, H3 lysine-9 specific 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6031] [GtoPdb: 2651] [UniProtKB: Q9H9B1] | ||||||||
| ChEMBL | Inhibition of EHMT1 (unknown origin) by HMT assay | B | 6.64 | pIC50 | 230 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| lysine methyltransferase 2A/Histone-lysine N-methyltransferase MLL in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1293299] [GtoPdb: 2688] [UniProtKB: Q03164] | ||||||||
| ChEMBL | Inhibition of MLL (unknown origin) by HMT assay | B | 5.64 | pIC50 | 2300 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| nuclear receptor binding SET domain protein 2/Histone-lysine N-methyltransferase NSD2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3108645] [GtoPdb: 3220] [UniProtKB: O96028] | ||||||||
| ChEMBL | Inhibition of recombinant human N-terminal GST-tagged NSD2 CD (941 to 1240 residues) expressed in Escherichia coli using SAM as substrate in presence of nucleosomes by AlphaLISA method | B | 4.41 | pIC50 | 39100 | nM | IC50 | Eur J Med Chem (2021) 222: 113592-113592 [PMID:34147909] |
| SET domain containing 7, histone lysine methyltransferase/Histone-lysine N-methyltransferase SETD7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5523] [GtoPdb: 2703] [UniProtKB: Q8WTS6] | ||||||||
| ChEMBL | Inhibition of SETD7 (unknown origin) | B | 4.33 | pIC50 | 47000 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| ChEMBL | Inhibition of SETD7 (unknown origin) by HMT assay | B | 4.52 | pIC50 | 30000 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| SET domain bifurcated histone lysine methyltransferase 1/Histone-lysine N-methyltransferase SETDB1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2321646] [GtoPdb: 2705] [UniProtKB: Q15047] | ||||||||
| ChEMBL | Inhibition of SETDB1 (unknown origin) by HMT assay | B | 5.66 | pIC50 | 2200 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| SUV39H1 histone lysine methyltransferase/Histone-lysine N-methyltransferase SUV39H1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795118] [GtoPdb: 2715] [UniProtKB: O43463] | ||||||||
| ChEMBL | Inhibition of SUV39H1 | B | 5.31 | pKi | 4900 | nM | Ki | J Med Chem (2012) 55: 8066-8074 [PMID:22924785] |
| ChEMBL | Inhibition of SUV39H1 (unknown origin) by HMT assay | B | 5.92 | pIC50 | 1200 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| SUV39H2 histone lysine methyltransferase/Histone-lysine N-methyltransferase SUV39H2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795177] [GtoPdb: 2716] [UniProtKB: Q9H5I1] | ||||||||
| ChEMBL | Inhibition of SUV39H2 (unknown origin) by HMT assay | B | 4.49 | pIC50 | 32000 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| ChEMBL | Inhibition of SUV39H2 (unknown origin) | B | 4.66 | pIC50 | 22000 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| lysine methyltransferase 5C/Histone-lysine N-methyltransferase SUV420H2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2321644] [GtoPdb: 2718] [UniProtKB: Q86Y97] | ||||||||
| ChEMBL | Inhibition of SUV420H2 (unknown origin) by HMT assay | B | 5 | pIC50 | 10000 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| Indolethylamine N-methyltransferase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2131] [UniProtKB: O95050] | ||||||||
| ChEMBL | Inhibitory constant towards indole N-methyl-transferase | B | 5.7 | pKi | 2000 | nM | Ki | J Med Chem (1983) 26: 1470-1477 [PMID:6620306] |
| methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit/N6-adenosine-methyltransferase catalytic subunit in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4739695] [GtoPdb: 3181] [UniProtKB: Q86U44] | ||||||||
| ChEMBL | Inhibition of recombinant METLL3 (unknown origin) expressed in baculovirus infected Sf9 cells assessed as decrease in N6-methyladenosine level in oligonucleotide substrate by TR-FRET assay | B | 6.23 | pIC50 | 590 | nM | IC50 | J Med Chem (2021) 64: 12738-12760 [PMID:34431664] |
| nicotinamide N-methyltransferase/Nicotinamide N-methyltransferase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2346486] [GtoPdb: 3205] [UniProtKB: P40261] | ||||||||
| ChEMBL | Inhibition of wild-type human full length NNMT expressed in Escherichia coli BL21(DE3) cells assessed as reduction in 1-methyl-nicotinamide formation pre-incubated for 10 mins followed by AdoMet and nicotinamide addition measured after 30 mins by UHP-HILIC/Q-TOF-MS analysis | B | 4.45 | pIC50 | 35300 | nM | IC50 | J Med Chem (2019) 62: 6597-6614 [PMID:31265285] |
| SET and MYND domain containing 2/N-lysine methyltransferase SMYD2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2169716] [GtoPdb: 2714] [UniProtKB: Q9NRG4] | ||||||||
| ChEMBL | Inhibition of SMYD2 (unknown origin) by HMT assay | B | 6.74 | pIC50 | 180 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 1532-1537 [PMID:25746813] |
| Nonstructural protein 5 in Dengue virus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4295629] [UniProtKB: V5TFZ2] | ||||||||
| ChEMBL | Inhibition of Dengue virus ribose 2'-O methyltransferase using RNA substrate after 20 mins in presence of [methyl-3H]-AdoMet by microbeta counting analysis | B | 6.31 | pIC50 | 490 | nM | IC50 | J Med Chem (2016) 59: 5622-5649 [PMID:26771861] |
| Phenylethanolamine N-methyltransferase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4617] [GtoPdb: 2496] [UniProtKB: P11086] | ||||||||
| ChEMBL | Competitive inhibition of C-terminal hexahistidine tag in human recombinant PNMT expressed in Escherichia coli assessed as inhibition constant using PEA as substrate in presence of 100 uM AdoMet as co-substrate by Sigma-plot analysis | B | 4.85 | pKi | 14000 | nM | Ki | J Med Chem (2020) 63: 13878-13898 [PMID:33147410] |
| Phenylethanolamine N-methyltransferase in Bovine (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2331] [UniProtKB: P10938] | ||||||||
| ChEMBL | Inhibition constant was evaluated against PNMT | B | 4.21 | pKi | 62300 | nM | Ki | J Med Chem (1985) 28: 478-482 [PMID:3981540] |
| ChEMBL | Inhibition constant was evaluated against PNMT | B | 4.54 | pKi | 29000 | nM | Ki | J Med Chem (1985) 28: 478-482 [PMID:3981540] |
| protein arginine methyltransferase 5 /PRMT5/MEP50 complex in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL3137261] [GtoPdb: 1256] [UniProtKB: O14744, Q9BQA1] | ||||||||
| ChEMBL | Inhibition of recombinant human N-terminal FLAG-tagged PRMT5 (2 to end residues) /human N-terminal His-tagged MEP50 (2 to end residues) expressed in HEK293F cells using substrate pretreated for 15 mins followed by substrate and [3H]-SAM addition measured after 60 mins by scintillation proximity assay | B | 6.22 | pIC50 | 600 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 1476-1483 [PMID:29628326] |
| ChEMBL | Inhibition of recombinant human N-terminal FLAG-tagged PRMT5 (2 to end residues) /human N-terminal His-tagged MEP50 (2 to end residues) expressed in HEK293F cells pretreated for 15 mins followed by substrate and [3H]-SAM addition measured after 60 mins by scintillation proximity assay | B | 6.25 | pIC50 | 560 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 3693-3699 [PMID:30366617] |
| protein arginine methyltransferase 1 /Protein-arginine N-methyltransferase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5524] [GtoPdb: 1252] [UniProtKB: Q99873] | ||||||||
| ChEMBL | Inhibition of PRMT1 | B | 6.4 | pKi | 400 | nM | Ki | J Med Chem (2012) 55: 8066-8074 [PMID:22924785] |
| ChEMBL | Inhibition of recombinant human N-terminal GST-tagged PRMT1 (2 to end residues) expressed in baculovirus infected Sf9 insect cells using biotinylated histone H4 peptide as substrate preincubated for 15 mins followed by substrate/[3H]-SAM addition measured after 60 mins by microbeta liquid scintillation counting analysis | B | 6.26 | pIC50 | 550 | nM | IC50 | Bioorg Med Chem Lett (2017) 27: 4635-4642 [PMID:28927791] |
| ChEMBL | Inhibition of PRMT1 (unknown origin) using biotinylated histone H4-derived peptide as substrate after 60 mins by AlphaLISA assay | B | 6.3 | pIC50 | 500 | nM | IC50 | Bioorg Med Chem Lett (2015) 25: 5449-5453 [PMID:26428871] |
| ChEMBL | Displacement of [3H]-SAM from recombinant His6-tagged PRMT1 (unknown origin) expressed in Escherichia coli BL21(DE3) incubated for 5 mins prior to H4(1 to 20)-BTN peptide addition measured after 8 mins by scintillation proximity assay | B | 6.38 | pIC50 | 420 | nM | IC50 | J Med Chem (2015) 58: 1228-1243 [PMID:25559100] |
| protein arginine methyltransferase 3/Protein arginine N-methyltransferase 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5891] [GtoPdb: 1254] [UniProtKB: O60678] | ||||||||
| ChEMBL | Inhibition of PRMT3 (unknown origin) | B | 5.7 | pIC50 | 2000 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| ChEMBL | Inhibition of recombinant human PRMT3 using histone H4 as substrate by hotspot assay | B | 6.12 | pIC50 | 760 | nM | IC50 | Eur J Med Chem (2020) 189: 112023-112023 [PMID:31978781] |
| ChEMBL | Inhibition of recombinant human PRMT8 using histone H4 as substrate by hotspot assay | B | 6.96 | pIC50 | 110 | nM | IC50 | Eur J Med Chem (2020) 189: 112023-112023 [PMID:31978781] |
| protein arginine methyltransferase 5 /Protein arginine N-methyltransferase 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795116] [GtoPdb: 1256] [UniProtKB: O14744] | ||||||||
| ChEMBL | Inhibition of human full length PRMT5 expressed in Sf9 cells | B | 4.3 | pIC50 | >50000 | nM | IC50 | ACS Med Chem Lett (2015) 6: 408-412 [PMID:25893041] |
| ChEMBL | Inhibition of PRMT5 (unknown origin) | B | 6.7 | pIC50 | 200 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4518-4522 [PMID:27485386] |
| protein arginine methyltransferase 7 /Protein arginine N-methyltransferase 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3562175] [GtoPdb: 1258] [UniProtKB: Q9NVM4] | ||||||||
| ChEMBL | Inhibition of human full length PRMT7 expressed in Sf9 cells | B | 4.3 | pIC50 | >50000 | nM | IC50 | ACS Med Chem Lett (2015) 6: 408-412 [PMID:25893041] |
| ChEMBL | Inhibition of recombinant human PRMT7 using GST-GAR as substrate by hotspot assay | B | 6.96 | pIC50 | 110 | nM | IC50 | Eur J Med Chem (2020) 189: 112023-112023 [PMID:31978781] |
| rRNA adenine N-6-methyltransferase in Streptococcus pneumoniae (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2757] [UniProtKB: P21236] | ||||||||
| ChEMBL | Inhibitory activity against ErmAM methylase | B | 4.4 | pKi | 40000 | nM | Ki | J Med Chem (1999) 42: 3852-3859 [PMID:10508434] |
| ChEMBL | Inhibition of ErmAM methylase | B | 4.4 | pKi | 40000 | nM | Ki | Bioorg Med Chem Lett (2000) 10: 433-437 [PMID:10743942] |
| tRNA (guanine-N(1)-)-methyltransferase in Mycobacterium tuberculosis (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523933] [UniProtKB: P9WFY7] | ||||||||
| ChEMBL | Binding affinity to full length Mycobacterium tuberculosis tRNA (guanine(37)-N1)-methyltransferase expressed in Escherichia coli BL21 (DE3) by surface plasmon resonance assay | B | 5 | pKd | 10100 | nM | Kd | J Med Chem (2019) 62: 7788-7805 [PMID:31442049] |
| tRNA (guanine-N(1)-)-methyltransferase in Staphylococcus aureus (strain NCTC 8325 / PS 47) (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523934] [UniProtKB: Q2FZ43] | ||||||||
| ChEMBL | Binding affinity to full length Staphylococcus aureus tRNA (guanine(37)-N1)-methyltransferase expressed in Escherichia coli BL21 (DE3) by surface plasmon resonance assay | B | 5.48 | pKd | 3300 | nM | Kd | J Med Chem (2019) 62: 7788-7805 [PMID:31442049] |
| tRNA (guanine-N(1)-)-methyltransferase in Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM14847 / LMG 12228 / 1C / PRS 101 / PAO1) (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523932] [UniProtKB: Q9HXQ1] | ||||||||
| ChEMBL | Binding affinity to Pseudomonas aeruginosa tRNA (guanine(37)-N1)-methyltransferase (Leu5 to Asp25 residues) expressed in Escherichia coli BL21 (DE3) Rosetta T1R cells by surface plasmon resonance assay | B | 5.23 | pKd | 5900 | nM | Kd | J Med Chem (2019) 62: 7788-7805 [PMID:31442049] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
